Purple Biotech (PPBT) Non-Current Assets (2015 - 2026)
Purple Biotech (PPBT) posted quarterly Non-Current Assets of $7.6 million for Q1 2026, down 72.8% year-over-year from $28.1 million in Q1 2025, and down 0.88% quarter-over-quarter from $7.7 million in Q4 2025.
Purple Biotech (PPBT) Non-Current Assets (2015 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Non-Current Assets for 12 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 72.8% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $91.9 million (down 18.56% YoY), while the FY2025 annual figure was $7.7 million, down 72.61% from the prior year.
- Non-Current Assets slipped to $7.6 million in Q1 2026 per PPBT's latest filing, from $7.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $28.7 million in Q1 2023 and bottomed at $7.6 million in Q1 2026.
- Historically, Non-Current Assets has averaged $24.8 million across 5 years, with a median of $28.1 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Assets surged 33.46% — and 2026, when it plunged 72.8%.
- Purple Biotech's Non-Current Assets stood at $21.4 million in 2022, then soared by 33.46% to $28.5 million in 2023, then declined by 1.35% to $28.1 million in 2024, then sank by 72.61% to $7.7 million in 2025, then dropped by 0.88% to $7.6 million in 2026.
- Business Quant data shows PPBT's Non-Current Assets at $7.6 million in Q1 2026, $7.7 million in Q4 2025, and $28.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Purple Biotech | 130.35 | 130.35 | - | 7.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.64 Mn |
| Dec 31, 2025 | 7.71 Mn |
| Sep 30, 2025 | 28.29 Mn |
| Jun 30, 2025 | 28.07 Mn |
| Mar 31, 2025 | 28.08 Mn |
| Dec 31, 2024 | 28.13 Mn |
| Sep 30, 2024 | 28.17 Mn |
| Jun 30, 2024 | 28.20 Mn |
| Mar 31, 2024 | 28.46 Mn |
| Dec 31, 2023 | 28.51 Mn |
| Sep 30, 2023 | 28.55 Mn |
| Jun 30, 2023 | 28.62 Mn |
| Mar 31, 2023 | 28.67 Mn |
| Dec 31, 2022 | 21.37 Mn |
| Sep 30, 2022 | 24.24 Mn |
| Jun 30, 2022 | 24.29 Mn |
| Mar 31, 2022 | 24.40 Mn |
| Dec 31, 2021 | 21.73 Mn |
| Sep 30, 2021 | 26.43 Mn |
| Jun 30, 2021 | 26.49 Mn |